VAR

Varian Medical Systems, Inc.

VAR

Overview Fund Activity

Delisted

VAR was delisted on the 14th of April, 2021.

Back to rankings

Financial journalist opinion

Varian Announces CE Mark for Embozene in Genicular Artery Embolisation, Expanding Treatment for Knee Osteoarthritis

PALO ALTO, Calif.--(BUSINESS WIRE)--Varian, a Siemens Healthineers company, announced today that its Embozene microspheres have received CE Marking for Genicular Artery Embolisation (GAE) for knee osteoarthritis. This regulatory milestone makes Embozene the first—and only—embolic agent to be CE Marked specifically for GAE, a minimally invasive procedure intended to target inflammation and help relieve pain in patients with knee osteoarthritis. Knee osteoarthritis is widespread, with a reported.

Varian Announces CE Mark for Embozene in Genicular Artery Embolisation, Expanding Treatment for Knee Osteoarthritis

Varian Completes Enrollment and Treatment in FAST-02 Clinical Trial of Flash Therapy in Treating Thoracic Bone Metastases

PALO ALTO, Calif.--(BUSINESS WIRE)-- #varian--Varian, a Siemens Healthineers company, has announced the successful completion of enrollment and treatment in its FAST-02 (Flash Radiotherapy for the Treatment of Symptomatic Bone Metastases in the Thorax) clinical trial. The FAST-02 study targets painful bone metastases in the thoracic region and represents a significant step toward bringing this investigational radiotherapy treatment into clinical practice. The trial was conducted at Cincinnati Children's.

Varian Completes Enrollment and Treatment in FAST-02 Clinical Trial of Flash Therapy in Treating Thoracic Bone Metastases

Varian's RapidArc Dynamic Solution Unlocks New Dimensions in Treatment Planning and Delivery

PALO ALTO, Calif.--(BUSINESS WIRE)-- #VARIAN--Varian's RapidArc Dynamic Solution Unlocks New Dimensions in Treatment Planning and Delivery.

Varian's RapidArc Dynamic Solution Unlocks New Dimensions in Treatment Planning and Delivery

Varian Announces 10-year Transformational Oncology Collaboration with Ballad Health to Bring Advanced Treatment Solutions to Rural Communities

PALO ALTO, Calif.--(BUSINESS WIRE)-- #VARIAN--Varian, a Siemens Healthineers company, announced a 10-year agreement with Ballad Health, to bring advanced oncology treatment services to serve patients in rural communities across the Appalachian Highlands in Northeast Tennessee, Southwest Virginia, northwestern North Carolina, and southeastern Kentucky. The transformational oncology collaboration with the Johnson City, Tennessee-based health system, is designed to deliver advanced treatment technology thro.

Varian Announces 10-year Transformational Oncology Collaboration with Ballad Health to Bring Advanced Treatment Solutions to Rural Communities

Varian Launches HyperSight™ for TrueBeam in Asia Pacific: Boosting Accuracy and Efficiency in Radiotherapy Treatment

Palo Alto, California, Aug. 26, 2024 (GLOBE NEWSWIRE) -- Varian, a Siemens Healthineers company, today announced the launch of HyperSight™ imaging solution for its TrueBeam and Edge systems across the Asia Pacific region (excluding China). This upgrade gives clinicians unparalleled image quality, enhancing their ability to deliver precise and efficient radiation therapy treatments. HyperSight optimizes workflows across Varian's entire suite of linear accelerators, enabling more tailored treatment for each patient.

Varian Launches HyperSight™ for TrueBeam in Asia Pacific: Boosting Accuracy and Efficiency in Radiotherapy Treatment

Siemens Healthineers Q1 sales beat expectations on strong Varian unit

German medical equipment maker Siemens Healthineers on Thursday posted first-quarter revenue above expectations and an operating result in line with consensus, driven by its U.S. cancer treatment unit Varian.

See News Rankings

Charts implemented using Lightweight Charts™